SCHOTT TOPPAC® freeze Wins Pharma Innovation Award

  • SCHOTT TOPPAC® freeze was among 13 winners chosen by Pharma Manufacturing editors and industry reviewers
  • Prefillable polymer syringes protect deep-cold medications that require storage and transport at temperatures approaching -100℃
  • The product launched in May 2023 and gave pharmaceutical companies a way to protect mRNA-based therapies, cell and gene therapies, and other medications

RYE BROOK, N.Y.–(BUSINESS WIRE)–SCHOTT, the international technology group and inventor of specialty glass, was among the winners of the Pharma Innovation Award for its SCHOTT TOPPAC® freeze prefillable polymer syringes. Pharma Manufacturing bestowed the honor for SCHOTT TOPPAC® freeze’s trailblazing solution to protecting deep-cold medications at temperatures approaching -100°C. The innovation highlights the impact of SCHOTT’s R&D team. The company invests 4% of its revenue into R&D activities to promote sustainable growth, and those efforts have spurred 3,500 worldwide patents.

SCHOTT TOPPAC® freeze was introduced to the market in May 2023 to support the increasing number of medications that require frozen conditions to remain stable throughout the supply chain, from filling to administration. The syringes are made of cyclic olefin copolymer, are break-resistant, biologically inert, and feature advanced barrier properties to ensure drug stability.

“Winning the Pharma Innovation Award is an important accolade for our syringe that is changing the drug development pipeline in its first year,” said Patrick Gallagher, Vice President and Head of Polymer Solutions at SCHOTT Pharma. “The success of SCHOTT TOPPAC® freeze highlights our commitment to evolving the pharmaceutical industry, offering unparalleled safety and stability for the next generation of medications, which require precise temperature controls.”

Quickly, SCHOTT TOPPAC® freeze has had a big impact on the market. Two industry-leading pharmaceutical manufacturers have selected this syringe for their entire mRNA vaccine pipelines. This innovation, and quick demand for it, made the product worthy of one of the 13 awards bestowed by Pharma Manufacturing, which cites the awards are “a tribute to those who listen to the needs of the market and their customers, and a result, have distinguished themselves as leaders in pharma equipment and technology.”

Every minute, more than 25,000 patients safely receive an injection stored in one of SCHOTT’s primary packaging products. SCHOTT TOPPAC® freeze is another example of how SCHOTT puts patients first by making drug delivery safe, easy, and real.

Pioneering – responsibly – together.

These attributes characterize SCHOTT as a manufacturer of high-tech materials based on specialty glass. Founder Otto Schott is considered its inventor and became the pioneer of an entire industry. Always opening up new markets and applications with a pioneering spirit and passion – this is what has driven the #glasslovers at SCHOTT for more than 130 years. Represented in 34 countries, the company is a highly skilled partner for high-tech industries: Healthcare, Home Appliances & Living, Consumer Electronics, Semiconductors & Datacom, Optics, Industry & Energy, Automotive, Astronomy & Aerospace. In the fiscal year 2021, its 17,300 employees generated sales of 2.5 billion euros. SCHOTT AG is owned by the Carl Zeiss Foundation, one of the oldest foundations in Germany. It uses the Group’s dividends to promote science. As a foundation company, SCHOTT has anchored responsibility for employees, society and the environment deeply in its DNA. The goal is to become a climate-neutral company by 2030.


Rina Della Vecchia

SCHOTT North America

Matt McLoughlin

Gregory FCA

error: Content is protected !!